• Luspatercept in low-risk MDS-RS patients reduces high suppressive Tregs and mMDSC.

  • Low mMDSC levels and active CTL response may represent predictive markers for Luspatercept response in MDS-RS patients.

This content is only available as a PDF.

Author notes

Data Sharing: For original data, please contact valentina.rubino@unina.it

© 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
2025

Article PDF first page preview

First page of Luspatercept treatment affects immune regulatory subsets in subjects with MDS with Ring Sideroblasts

Supplemental data

Supplemental Methods, References, Tables, and Figures- pdf file